Accessibility Menu
ProKidney logo

ProKidney(NASDAQ) PROK

Market Cap$316.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-84%
5 Year-84%
1 Year-44%
1 Month-19%
$1.54
-2.53%
-0.04Today
After hours$1.54-$0.01 (-0.33%)
ProKidney last closing stock price
MetricPriceDate
Last closeUSD 1.542026-07-31
ProKidney stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.67%USD 1.502026-07-24
1 month-18.52%USD 1.892026-07-01
3 month-20.21%USD 1.932026-05-01
Year to date-31.25%USD 2.242025-12-31
1 year-44.4%USD 2.772025-07-31
3 year-88.23%USD 13.082023-08-01
5 year-84.37%USD 9.852021-07-30
Since inception-84.37%USD 10.112021-06-30

ProKidney Financials at a Glance

Market Cap

$316.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$889.00K

Net Income (TTM)

-$74.84M

EPS (TTM)

-$0.53

P/E Ratio

-2.92

Dividend

$0.00

Beta (Volatility)

1.39 (Average)

Price

$1.54

Volume

809,088

Open

$1.56

Previous Close

$1.54

Daily Range

$1.51 - $1.58

52-Week Range

$1.45 - $3.55

Estimated Earnings Date

Aug 11, 2026

PROK News

Foolcom-Featured.png

ProKidney Reports 78 Percent Gain in Q2

Motley Fool Markets TeamAug 12, 2025
happy-investors-checking-holdings

Meet the Biotech Stock That Rocketed 775% Higher

Cory RenauerJul 22, 2025
Person working in a lab.

This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy?

David Jagielski, CPAJul 17, 2025
adaptimmune

Why Shares of ProKidney Were Dropping Thursday

James HalleyOct 12, 2023

PROK: Motley Fool Moneyball Superscore

48

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ProKidney

ProKidney helps patients with advanced kidney disease. It uses a person's own cells to fix kidneys. This avoids the need for risky organ transplants.

Cell Therapy and Clinical Trials

  • Rilparencel: Personalized cell therapy in Phase 3 trials for chronic kidney disease and type 2 diabetes.
  • Selected Renal Cells: Specialized cells prepared from the patient's own tissue to help preserve kidney function.
  • Property Leasing: Rental of extra space within the company's manufacturing buildings to other businesses.

Recent Changes and Strategic Deals

  • Completed a domestication process to move the legal headquarters from the Cayman Islands to Delaware in July 2025.
  • Terminated a 2024 sales agreement to start a new $200 million stock sale plan with Jefferies in 2025.
  • Merged with Social Capital Suvretta Holdings Corp. III in July 2022 to become a publicly traded company.
  • Amended the clinical study protocol for rilparencel to focus on specific stages of advanced kidney disease.

Why This Treatment Stands Out

ProKidney delivers treatment through a minimally invasive procedure directly into the kidney. Because the therapy uses the patient's own cells, it removes the need for drugs that prevent organ rejection.

Evaluating Recent Financial Data

  • Operating loss worsened to $44.9 million in Q1 2026, deepening 8.6% from the previous year.
  • Net loss reached $22.6 million in Q1 2026, a 35% increase in losses from Q1 2025.
  • Lease revenue from building tenants fell to $226,000 in Q1 2026, down 1.7% year-over-year.
  • Cash and marketable securities totaled $225 million as of March 31, 2026.

A Specialized Biotech Journey

ProKidney has evolved from a private research firm into a late-stage clinical developer. Its success depends on proving its personalized cell therapy can safely preserve kidney function in large human trials.

AI Generated • May 19, 2026

Industry

Biotechnology

Sector

Health Care

Employees

231

CEO

Bruce Culleton, MD, MBA

Website

www.prokidney.com

Headquarters

Winston-Salem, NC 27103, US

PROK Financials

Key Financial Metrics (TTM)

Gross Margin

-224.41%

Operating Margin

-18959.73%

Net Income Margin

-8418.00%

Return on Equity

7.40%

Return on Capital

N/A

Return on Assets

-25.56%

Earnings Yield

-34.25%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$316.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

205.20M

Volume

809.09K

Avg. Volume

1.15M

Financials (TTM)

Gross Profit

-$2.00M

Operating Income

-$168.55M

EBITDA

-$150.42M

Operating Cash Flow

-$132.21M

Capital Expenditure

-$17.85M

Free Cash Flow

-$150.06M

Cash & ST Invst.

$224.94M

Total Debt

$3.78M

ProKidney Performance Analysis

ProKidney annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 76,000N/A
20252025-12-31USD 893,0001075.0%
ProKidney sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-3.9%
Q32025-09-30-1.8%
Q42025-12-313.7%
Q12026-03-310.4%
ProKidney annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.7695.9%
20232023-12-31USD -0.57-67.3%
20242024-12-31USD -0.628.7%
20252025-12-31USD -0.52-17.6%
ProKidney sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-307.7%
Q42025-12-31-16.7%
Q12026-03-31-14.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$226.00K

-1.7%

Gross Profit

-$1.21M

-625.7%

Gross Margin

-5.35%

N/A

Market Cap

$316.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.37M

N/A

Employees

231

N/A

Net Income

-$22.58M

-35.0%

EBITDA

-$41.17M

-15.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$224.94M

-31.5%

Total Debt

$3.78M

+12.3%

Accounts Receivable

$1.03M

-41.1%

Inventory

$0.00

N/A

Long Term Debt

$2.68M

+6.5%

Short Term Debt

$1.11M

+29.3%

Return on Assets

-25.56%

N/A

Return on Invested Capital

-63.16%

N/A

Free Cash Flow

-$45.47M

-48.0%

Operating Cash Flow

-$41.68M

-40.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RZLTRezolute, Inc.
$4.72-3.28%
PRMEPrime Medicine, Inc.
$2.92-3.31%
KURAKura Oncology, Inc.
$9.01-3.22%
EYPTEyePoint Pharmaceuticals, Inc.
$12.25-4.74%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About PROK

What is the current price of ProKidney?

ProKidney is trading at $1.54 per share.

What is the 52-week range for ProKidney?

Over the past 52 weeks, ProKidney has traded between $1.45 and $3.55.

How much debt does ProKidney have?

As of the most recent reporting period, ProKidney reported total debt of $3.78M.

How much cash does ProKidney have on hand?

ProKidney reported $101.90M in cash and cash equivalents in its most recent financial results.

What is ProKidney’s dividend yield?

ProKidney does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services